Log in
Enquire now
‌

US Patent 10144737 Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

Patent 10144737 was granted and assigned to Jiangsu Hengrui Medicine on December, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Patent abstract

The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10144737 Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo